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Abstract
Although the ability to make triglycerides is essential for normal physiology, excess accumulation
of triglycerides results in obesity and is associated with insulin resistance. Inhibition of triglyceride
synthesis, therefore, may represent a feasible strategy for the treatment of obesity and type 2
diabetes. Acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) is one of two DGAT enzymes that
catalyze the final reaction in the known pathways of mammalian triglyceride synthesis. Mice lacking
DGAT1 have increased energy expenditure and insulin sensitivity and are protected against diet-
induced obesity and glucose intolerance. These metabolic effects of DGAT1 deficiency result in
part from the altered secretion of adipocyte-derived factors. Studies of DGAT1-deficient mice have
helped to provide insights into the mechanisms by which cellular lipid metabolism modulates
systemic carbohydrate and insulin metabolism, and a better understanding of how DGAT1
deficiency enhances energy expenditure and insulin sensitivity may identify additional targets or
strategies for the treatment of obesity and type 2 diabetes.
Introduction
Triglycerides (triacylglycerols) are neutral lipids consisting
of a glycerol backbone and three long-chain fatty acids. In
addition to representing a major form of stored energy in
the adipose tissue and skeletal muscle, triglycerides are an
integral component of lipoprotein particles synthesized
by the liver and small intestine, skin sebum secreted by
sebaceous glands, and milk produced by mammary
glands. Clearly, the ability to make triglycerides is essen-
tial for normal physiology.
Excess triglyceride accumulation, however, leads to obes-
ity and, particularly when it occurs in non-adipose tissues,
is associated with insulin resistance. Inhibition of triglyc-
eride synthesis, therefore, represents a potential therapeu-
tic strategy for human obesity and type 2 diabetes. Until
recently, it had been unclear whether disrupting triglycer-
ide synthesis would be beneficial or would instead cause
significant adverse consequences. The generation of mice
lacking acyl CoA:diacylglycerol acyltransferase 1
(DGAT1), a key enzyme in the triglyceride synthesis path-
way, has helped to provide insights into the metabolic
effects of inhibiting triglyceride synthesis in animals [1].
Role of DGAT1 in triglyceride synthesis
DGAT1 is one of two DGAT enzymes that catalyze the
linkage of a sn-1,2-diacylglycerol with a fatty acyl CoA to
form a triglyceride molecule. In cells, the reaction cata-
lyzed by DGAT1 takes place primarily in the endoplasmic
reticulum. Although DGAT1 is widely expressed in tissues,
the highest expression levels in humans are in tissues typ-
ically associated with triglyceride metabolism, in particu-
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lar the adipose tissue, small intestine, and liver. The tissue
distribution pattern is similar in humans and mice [2].
Although DGAT1 is primarily identified as a triglyceride
synthesis enzyme, recent findings indicate that it is also
capable of catalyzing the formation of diacylglycerols,
waxes, and retinyl esters in vitro [3]. It will be of interest to
determine the relative importance of each of these func-
tions in vivo.
Decreased adiposity and tissue triglyceride levels in 
DGAT1-deficient mice
DGAT1-deficient (Dgat1-/-) mice are viable and have
~50% less adipose mass and smaller adipocytes than wild-
type (WT) mice on a chow diet. Triglyceride levels in the
adipose tissue and skeletal muscle of Dgat1-/- mice are also
decreased by ~30–40%. Although differences in liver trig-
lyceride levels are not statistically significant in chow-fed
conditions, on a high-fat diet liver triglyceride levels are
significantly lower in Dgat1-/- mice than in WT mice [1,4].
Tissue levels of diacylglycerol, a substrate for the DGAT
reaction, are not elevated, and in fact tend to be lower in
the skeletal muscle and liver of Dgat1-/- mice. These find-
ings may be explained in part by the loss of acyl
CoA:monoacylglycerol acyltransferase (MGAT) activity
mediated by DGAT1 [3]. DGAT1 deficiency also alters the
fatty acid composition of triglycerides in the adipose tis-
sue and skeletal muscle, resulting in a relative decrease in
monounsaturated (16:1 and 18:1) fatty acids and a rela-
tive increase in saturated (16:0 and 18:0) fatty acids [4].
Although mechanisms of this altered fatty acid composi-
tion remain incompletely understood, it may reflect a
decreased utilization of saturated lipids in DGAT1-medi-
ated triglyceride synthesis. Such substrate preference has
been reported for murine MGAT2, which catalyzes the for-
mation of diacylglycerols in the small intestine [5].
Despite the absence of DGAT1, serum triglyceride levels
are normal in Dgat1-/- mice, suggesting that either DGAT1
does not play a rate-limiting role in hepatic triglyceride
secretion, or alternative mechanisms can compensate for
the loss of DGAT1 to maintain normal serum triglyceride
levels [1]. Serum levels of free fatty acids are also similar
in WT and Dgat1-/- mice.
Increased insulin sensitivity in DGAT1-deficient mice
Correlating with the decreased adiposity, glucose metabo-
lism is enhanced in Dgat1-/-  mice, as evidenced by
decreased blood glucose concentrations after either an
intraperitoneal glucose load (Figure 1A) or an insulin
injection (Figure 1B) in Dgat1-/- mice. An increase in insu-
lin sensitivity is confirmed by results from hyperinsuline-
mic-euglycemic clamp studies (Figure 1C), in which
Dgat1-/- mice require a ~20% higher glucose infusion rate
than WT mice to maintain euglycemia [4]. Partial DGAT1
deficiency appears to increase insulin sensitivity as well, as
suggested by decreased blood glucose levels after intra-
peritoneal injections of insulin in inbred DGAT1-hetero-
zygous (Dgat1+/-) mice [6]. The increase in systemic
insulin sensitivity likely can be attributed to increased
insulin-stimulated glucose transport in the skeletal mus-
cle and white adipose tissue (WAT) [7].
Although the precise molecular mechanisms that mediate
these findings remain to be fully elucidated, insulin-stim-
ulated activities of phosphatidylinositol-3 kinase, protein
kinase B, and protein kinase Cλ, three key molecules in
the insulin signaling pathway, are increased in the skeletal
muscle of Dgat1-/- mice. In addition, levels of serine-phos-
phorylated insulin receptor substrate-1, a molecule impli-
cated in insulin resistance, are decreased in the skeletal
muscle and WAT of Dgat1-/- mice [7].
Obesity resistance and increased energy expenditure in 
DGAT1-deficient mice
When fed a high-fat diet, Dgat1-/- mice are resistant to
weight gain and accumulation of adipose mass, and
inbred  Dgat1+/-  mice have an intermediate phenotype
[1,6]. Because DGAT1 deficiency does not affect lean body
mass, reductions in fat pad mass and tissue triglyceride
levels most likely account for the differences in body
weight [1].
The decreased adiposity and resistance to diet-induced
obesity in Dgat1-/- mice result from an increase in total
energy expenditure [1]. The increased energy expenditure
Increased insulin sensitivity in Dgat1-/- mice Figure 1
Increased insulin sensitivity in Dgat1-/- mice. A. Glucose 
tolerance test. B. Insulin tolerance test. C. Hyperinsulinemic-
euglycemic clamp study. Reproduced with permission from 
[3].
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is attributable to at least two mechanisms - increased
ambulatory physical activity in either chow (unpublished
observations) or high-fat-fed conditions [1], and
increased expression of uncoupling protein 1 [4], which is
a major mediator of nonshivering thermogenesis in
rodents.
Interestingly, Dgat1-/- mice eat more than WT mice, and
the hyperphagia is more pronounced during exposure to
cold. When fasted in a cold environment, Dgat1-/- mice
develop hypothermia, which is associated with hypoglyc-
emia. These results suggest that the hyperphagia in Dgat1-
/- mice is a secondary mechanism that compensates for the
increased utilization of fuel substrates [8].
Altered expression of adipocyte-secreted factors in 
DGAT1-deficient mice
How DGAT1 deficiency increases energy expenditure and
insulin sensitivity remains incompletely understood.
However, one contributing mechanism is the altered
endocrine function of WAT in Dgat1-/- mice. Recent stud-
ies have identified WAT as an important endocrine organ
that regulates energy and glucose metabolism through
secreted factors such as leptin, adiponectin, and resistin.
Alterations in adipocyte size have been shown to correlate
with changes in the endocrine function of WAT, and mod-
ulating DGAT1 expression affects adipocyte size in mice
[4,9]. It is perhaps not surprising, then, that DGAT1 defi-
ciency affects the expression and secretion of several adi-
pocyte-derived factors that modulate energy and glucose
metabolism [10].
To determine whether the altered expression of adipocyte-
derived factors has physiological consequences, WAT
from  Dgat1-/- mice was transplanted into WT recipient
mice to assess its effects on glucose disposal and the
response to a high-fat diet. Remarkably, transplantation
of Dgat1-/- WAT conferred partial obesity resistance (Figure
2A), enhanced glucose disposal after a glucose load (Fig-
ure 2B), and increased activation of the insulin signaling
pathway in WT recipient mice [7,10]. In contrast, trans-
plantation of WT adipose tissue into Dgat1-/- mice did not
adversely affect their resistance to diet-induced obesity or
enhanced response to insulin. These results provide
strong evidence that the altered endocrine function of
Dgat1-/- WAT has beneficial effects on systemic energy and
glucose metabolism. Moreover, they suggest that these
effects likely result from an increased secretion of adi-
pocyte-derived factors by Dgat1-/- WAT [10]. It will be of
interest to better understand how DGAT1 deficiency alters
the endocrine function of the WAT, and which factors
contribute to the increased energy expenditure and insu-
lin sensitivity in Dgat1-/- mice.
Perspectives and future directions
The Dgat1-/- mouse is one of many genetically engineered
murine models characterized by enhanced energy and
glucose metabolism. For example, inactivation of other
key components of the lipid synthesis pathway (e.g.,
acetyl CoA carboxylase 2, stearoyl CoA desaturase 1, and
acylation stimulating protein) also results in obesity
resistance and/or improved glucose metabolism in mice
[11,12]. These results suggest the existence of a final com-
mon mechanism for increased energy expenditure, obes-
ity resistance, and enhanced glucose disposal. It is unclear
whether this common mechanism is mediated through
the central nervous system (e.g., hypothalamus) or occurs
directly in the peripheral tissues (e.g., adipose tissue, skel-
etal muscle). Given the complexity of regulating energy
and glucose metabolism, however, it most likely involves
multiple levels of interaction between the brain and the
periphery.
Recent knockout mouse models have also provided
insights into the mechanisms by which cellular lipid
metabolism modulates systemic carbohydrate and insulin
metabolism. The disruption of enzymes in the anabolic
process of lipid uptake and storage (e.g., lipoprotein
lipase, DGAT1) is more likely to enhance tissue glucose
disposal or insulin secretion, whereas disruptions of
enzymes in the catabolic process (e.g., hormone-sensitive
lipase) tend to impair insulin action or secretion [13]. In
these various knockout models, glucose disposal does not
appear to have a strong correlation with levels of plasma
free fatty acids, which have been hypothesized to be an
important correlative of insulin resistance. Rather, these
studies appear to support the notion that concentrations
of fatty acid-derived molecules (i.e., fatty acyl CoAs, dia-
cylglycerols) within cells, particularly myocytes, hepato-
cytes, and pancreatic β-cells, relate more directly to insulin
resistance [14,15].
Obesity resistance and enhanced glucose tolerance in WT  mice transplanted with Dgat1-/- WAT Figure 2
Obesity resistance and enhanced glucose tolerance in 
WT mice transplanted with Dgat1-/- WAT. A. Body 
weight response to high-fat feeding. Mice were placed on a 
high-fat diet one week after fat transplantation. B. Glucose 
tolerance test. Reproduced with permission from [9].Publish with BioMed Central    and   every 
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It is interesting that the disruption of lipid synthesis
enzymes in mice achieves several outcomes that are typi-
cally associated with carbohydrate restriction [16]. Further
research may help to determine whether mechanisms that
mediate the metabolic effects of lipid synthesis inhibition
also contribute to the beneficial effects of carbohydrate
restriction. Additionally, further study of the mechanisms
underlying the increased energy expenditure and
increased insulin sensitivity in these mouse models may
identify other novel therapeutic targets for human obesity
and type 2 diabetes.
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